Sort   by:  
 Page size 
MetabolomicsEmerging mechanisms and promising approaches in pancreatic cancer metabolism.

Pancreatic cancer is an aggressive cancer with a poor prognosis. Metabolic abnormalities are one of the hallmarks of pancreatic cancer, and pancreatic cancer cells can adapt to biosynthesis, energy intake and redox needs through metabolic reprogramming to tolerate nutrient deficiency and hypoxic ...

2025-03-26 | MTBLS12204 | MetaboLights
MetabolomicsUnravelling altered RNA metabolism in pancreatic cancer cells by liquid-chromatography coupling to ion mobility mass spectrometry
Ion mobility coupling to mass spectrometry facilitates an increase of resolution and chromatographic peak-capacity. Further coupling to liquid chromatography results in multi-dimensional analytical methods, especially suitable for complex matrices with structurally similar compounds. Modified nucleo...
2019-05-16 | MTBLS812 | MetaboLights
MetabolomicsContributions of the Microbiome-Derived Metabolome for Risk Assessment and Prognostication of Pancreatic Cancer

BACKGROUND Increasing evidence implicates microbiome involvement in the development and progression of pancreatic ductal adenocarcinoma (PDAC). Studies suggest that reflux of gut or oral microbiota can lead to colonization in the pancreas, resulting in dysbiosis that culminates ...

2023-08-09 | MTBLS7260 | MetaboLights
MetabolomicsELAPOR1 induces the classical/progenitor subtype and contributes to reduced disease aggressiveness through metabolic reprogramming in pancreatic cancer
Pancreatic ductal adenocarcinoma (PDAC) is a heterogeneous disease with distinct molecular subtypes described as classical/progenitor and basal-like/squamous PDAC. We hypothesized that integrative transcriptome and metabolome approaches can identify candidate genes whose inactivation contributes to ...
2024-04-02 | MTBLS9418 | MetaboLights
MetabolomicsIncreased glucose availability sensitizes pancreatic cancer to chemotherapy
Pancreatic cancer (Pancreatic Ductal Adenocarcinoma; PDAC) is highly resistant to chemotherapy. Effective alternative therapies have yet to emerge, and therefore, chemotherapy remains the best available systematic treatment. The discovery of safe and available adjuncts that can improve chemotherapeu...
2022-10-18 | MTBLS6000 | MetaboLights
MetabolomicsCYP51A1-mediated alkaliptosis resistance is a targetable vulnerability in pancreatic cancer

Alkaliptosis, a pH-dependent form of regulated cell death characterized by impaired lysosomal function and lethal alkalinization, holds promise as a target for cancer therapy. Here, we utilize mass spectrometry-based drug target, transcriptomic screens, and lipid metabolomics to explore the metab...

2025-02-28 | MTBLS9288 | MetaboLights
MetabolomicsCYP51A1-mediated alkaliptosis resistance is a targetable vulnerability in pancreatic cancer

Alkaliptosis, a pH-dependent form of regulated cell death characterized by impaired lysosomal function and lethal alkalinization, holds promise as a target for cancer therapy. Here, we utilize mass spectrometry-based drug target, transcriptomic screens and lipid metabolomics to explore the metabo...

2025-02-28 | MTBLS9283 | MetaboLights
MetabolomicsEMT alterations in the solute carrier landscape uncover SLC22A10/A15 imposed vulnerabilities in pancreatic cancer

The involvement of membrane-bound solute carriers (SLCs) in neoplastic transdifferentiation processes is poorly defined. Here, we examined changes in the SLC landscape during epithelial-mesenchymal transition (EMT) of pancreatic cancer cells. We show that two SLCs from the organic anion...

2021-10-15 | MTBLS1925 | MetaboLights
MetabolomicsHistone serotonylation promotes pancreatic cancer development via lipid metabolism remodeling

Neurotransmitter serotonin (5-hydroxytryptamine [5-HT]) has emerged to play parallel roles in both neurobiology and oncology. Apart from receptor-mediated signaling transduction pattern, serotonin can be covalently integrated into histone (the post-translational modification known as histone sero...

2025-06-13 | MTBLS12569 | MetaboLights
MetabolomicsLimited nutrient availability in the tumor microenvironment renders pancreatic tumors sensitive to allosteric IDH1 inhibitors

Nutrient-deprived conditions in the tumor microenvironment (TME) restrain cancer cell viability due to increased free radicals and reduced energy production. In pancreatic cancer cells, a cytosolic metabolic enzyme, wild-type isocitrate dehydrogenase 1 (wtIDH1), enables the adaptation to these co...

2022-04-29 | MTBLS4722 | MetaboLights
Sort   by:  
 Page size